Home › NDC Lookup › RxCUI directory › RxCUI 597770

Deferasirox 250 MG Tablet for Oral Suspension — RxCUI 597770

RxNorm drug concept · Semantic clinical drug
RxCUI 597770 Semantic clinical drug · SCD ● Current RxNorm concept 35 FDA products 62 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI597770
Official nameDeferasirox 250 MG Tablet for Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped35
Package NDCs mapped62
Reported Medicaid activity (SDUD)455 prescriptions · 9 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Deferasirox: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It removes extra iron that builds up in the body. That can happen after many blood transfusions, or in certain thalassemia conditions where you don't need regular transfusions. You...
  • You take it by mouth once a day, as a tablet, a tablet mixed in liquid, or granules, depending on your product. Your dose depends on your weight and kidney function. Follow your pr...
  • Deferasirox can affect your kidneys, liver and blood counts, sometimes seriously. Tests catch problems early, and ferritin checks help make sure your iron isn't removed too far. Pl...
  • Diarrhea, nausea, vomiting, stomach pain and rash are common. Call your doctor right away for yellow skin or eyes, black or bloody stools, severe stomach pain, big changes in urina...
📖 Read our full Deferasirox guide →

🕸️ Concept Web — How Deferasirox 250 MG Tablet for Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Deferasirox 250 MG Tablet for Oral Suspension RxCUI 597770

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Deferasirox 614373
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Exjade 614084
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Deferasirox Tablet for Oral Suspension 1869534
    • Deferasirox Oral Liquid Product 1157196
    • Deferasirox Oral Product 1157197
    • Deferasirox Tablet for Oral Suspension [Exjade] 1869537
    • Exjade Oral Liquid Product 1173264
    • Exjade Oral Product 1173265
    • Tablet for Oral Suspension 1861409
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Deferasirox 250 MG SCDC · 1869540
  • Deferasirox Tablet for Oral Suspension SCDF · 1869534
  • Deferasirox Oral Liquid Product SCDG · 1157196
  • Deferasirox Oral Product SCDG · 1157197

Brand-Name Concepts

  • Deferasirox 250 MG Tablet for Oral Suspension [Exjade] SBD · 616161
  • Deferasirox 250 MG [Exjade] SBDC · 1869542
  • Deferasirox Tablet for Oral Suspension [Exjade] SBDF · 1869537
  • Exjade Oral Liquid Product SBDG · 1173264
  • Exjade Oral Product SBDG · 1173265
  • Exjade BN · 614084

📦 FDA Products & Package NDCs

35 products · 62 package NDCs
62 package NDCs map to RxCUI 597770 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-0468-15 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0468-15) Exjade Novartis Pharmaceuticals Corporation 2005-11-30
00078-0469-15 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0469-15) Exjade Novartis Pharmaceuticals Corporation 2005-11-30
00078-0470-15 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0470-15) Exjade Novartis Pharmaceuticals Corporation 2005-11-30
00480-7011-56 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0480-7011-56) Deferasirox Teva Pharmaceuticals, Inc. 2024-11-01
00480-7012-56 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0480-7012-56) Deferasirox Teva Pharmaceuticals, Inc. 2024-11-01
00480-7013-56 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0480-7013-56) Deferasirox Teva Pharmaceuticals, Inc. 2024-11-01
43598-0854-05 500 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-854-05) Deferasirox Dr. Reddy's Laboratories Inc 2019-11-20
43598-0854-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-854-30) Deferasirox Dr. Reddy's Laboratories Inc 2019-11-20
43598-0854-90 90 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-854-90) Deferasirox Dr. Reddy's Laboratories Inc 2019-11-20
43598-0855-10 1000 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-855-10) Deferasirox Dr. Reddy's Laboratories Inc 2019-11-20
43598-0855-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-855-30) Deferasirox Dr. Reddy's Laboratories Inc 2019-11-20
43598-0855-90 90 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-855-90) Deferasirox Dr. Reddy's Laboratories Inc 2019-11-20
43598-0856-10 1000 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-856-10) Deferasirox Dr. Reddy's Laboratories Inc 2019-11-20
43598-0856-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-856-30) Deferasirox Dr. Reddy's Laboratories Inc 2019-11-20
43598-0856-90 90 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-856-90) Deferasirox Dr. Reddy's Laboratories Inc 2019-11-20
45963-0455-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (45963-455-30) Deferasirox Actavis Pharma, Inc. 2019-03-22
45963-0456-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (45963-456-30) Deferasirox Actavis Pharma, Inc. 2019-03-22
46708-0324-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (46708-324-30) Deferasirox Alembic Pharmaceuticals Limited 2019-11-21
46708-0325-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (46708-325-30) Deferasirox Alembic Pharmaceuticals Limited 2019-11-21
46708-0326-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (46708-326-30) Deferasirox Alembic Pharmaceuticals Limited 2019-11-21
62332-0324-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62332-324-30) Deferasirox Alembic Pharmaceuticals Inc. 2019-11-21
62332-0325-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62332-325-30) Deferasirox Alembic Pharmaceuticals Inc. 2019-11-21
62332-0326-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62332-326-30) Deferasirox Alembic Pharmaceuticals Inc. 2019-11-21
62756-0568-83 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-568-83) deferasirox Sun Pharmaceutical Industries, Inc. 2019-12-02
62756-0568-86 60 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-568-86) deferasirox Sun Pharmaceutical Industries, Inc. 2019-12-02
62756-0569-83 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-569-83) deferasirox Sun Pharmaceutical Industries, Inc. 2019-12-02
62756-0569-86 60 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-569-86) deferasirox Sun Pharmaceutical Industries, Inc. 2019-12-02
62756-0570-83 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-570-83) deferasirox Sun Pharmaceutical Industries, Inc. 2019-12-02
62756-0570-86 60 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-570-86) deferasirox Sun Pharmaceutical Industries, Inc. 2019-12-02
67877-0549-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (67877-549-30) Deferasirox Ascend Laboratories, LLC 2019-11-22
67877-0550-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (67877-550-30) Deferasirox Ascend Laboratories, LLC 2019-11-22
67877-0551-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (67877-551-30) Deferasirox Ascend Laboratories, LLC 2019-11-22
68462-0494-90 90 TABLET, FOR SUSPENSION in 1 BOTTLE (68462-494-90) deferasirox Glenmark Pharmaceuticals Inc., USA 2020-01-06
68462-0495-90 90 TABLET, FOR SUSPENSION in 1 BOTTLE (68462-495-90) deferasirox Glenmark Pharmaceuticals Inc., USA 2020-01-06
68462-0496-90 90 TABLET, FOR SUSPENSION in 1 BOTTLE (68462-496-90) deferasirox Glenmark Pharmaceuticals Inc., USA 2020-01-06
69452-0159-13 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69452-159-13) Deferasirox Bionpharma Inc. 2018-09-28
69452-0160-13 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69452-160-13) Deferasirox Bionpharma Inc. 2018-09-28
69452-0161-13 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69452-161-13) Deferasirox Bionpharma Inc. 2018-09-28
69539-0021-06 10 BLISTER PACK in 1 CARTON (69539-021-06) / 10 TABLET, FOR... Deferasirox MSN LABORATORIES PRIVATE LIMITED 2020-02-12
69539-0021-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-021-30) Deferasirox MSN LABORATORIES PRIVATE LIMITED 2019-11-20
69539-0021-90 90 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-021-90) Deferasirox MSN LABORATORIES PRIVATE LIMITED 2019-11-20
69539-0021-99 1000 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-021-99) Deferasirox MSN LABORATORIES PRIVATE LIMITED 2019-11-20
69539-0022-06 10 BLISTER PACK in 1 CARTON (69539-022-06) / 10 TABLET, FOR... Deferasirox MSN LABORATORIES PRIVATE LIMITED 2020-02-12
69539-0022-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-022-30) Deferasirox MSN LABORATORIES PRIVATE LIMITED 2019-11-20
69539-0022-90 90 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-022-90) Deferasirox MSN LABORATORIES PRIVATE LIMITED 2019-11-20
69539-0022-99 1000 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-022-99) Deferasirox MSN LABORATORIES PRIVATE LIMITED 2019-11-20
69539-0023-05 500 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-023-05) Deferasirox MSN LABORATORIES PRIVATE LIMITED 2019-11-20
69539-0023-06 10 BLISTER PACK in 1 CARTON (69539-023-06) / 10 TABLET, FOR... Deferasirox MSN LABORATORIES PRIVATE LIMITED 2020-02-12
69539-0023-30 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-023-30) Deferasirox MSN LABORATORIES PRIVATE LIMITED 2019-11-20
69539-0023-90 90 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-023-90) Deferasirox MSN LABORATORIES PRIVATE LIMITED 2019-11-20
Observed labelers: MSN LABORATORIES PRIVATE LIMITED (12) · Novadoz Pharmaceuticals LLC (12) · Dr. Reddy's Laboratories Inc (9) · Sun Pharmaceutical Industries, Inc. (6) · Alembic Pharmaceuticals Inc. (3) · Alembic Pharmaceuticals Limited (3) · +6 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.